GENOSYL Drug Patent Profile

Which patents cover Genosyl, and what generic alternatives are available?

Genosyl is a drug marketed by Vero Biotech Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has sixty-one patent family members in five countries.

The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Genosyl

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENOSYL

International Patents:	61
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENOSYL

US Patents and Regulatory Information for GENOSYL

GENOSYL is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes	9,604,028
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes	8,607,785		Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes	8,057,742
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes	11,103,669		Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes	11,511,252		Y

International Patents for GENOSYL

See the table below for patents covering GENOSYL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2025090727	二酸化窒素貯蔵カセット (NITROGEN DIOXIDE STORAGE CASSETTE)
Canada	2965159	CASSETTE DE STOCKAGE DE DIOXYDE D'AZOTE (NITROGEN DIOXIDE STORAGE CASSETTE)
Japan	2012179365	CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO)
Japan	2025090727	二酸化窒素貯蔵カセット (NITROGEN DIOXIDE STORAGE CASSETTE)
Japan	5567617

Supplementary Protection Certificates for GENOSYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0560928	2002C/003	Belgium		PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
0786264	SPC/GB08/019	United Kingdom		PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801

Investment Scenario, Market Dynamics, and Financial Trajectory for GENOSYL (Nitric Oxide Gas)

Last updated: February 3, 2026

Summary

GENOSYL, a pharmaceutical-grade nitric oxide (NO) gas, primarily marketed as INOmax, is used in critical care for pulmonary hypertension and other indications. Its market outlook is influenced by medical demand, regulatory landscape, technological innovations, and competitive dynamics. Despite a mature market, emerging therapeutic uses and regulatory shifts could shape its financial trajectory. This report analyzes current market conditions, growth drivers, and investment risks associated with GENOSYL.

---

What Is GENOSYL and How Does It Function?

GENOSYL (a brand of INOmax, nitrous oxide (NO) inhalation therapy) is a gaseous medicine that facilitates vasodilation in pulmonary circulation, making it vital for neonatal, adult cardiac, and respiratory care.

Key Specifications	Details
Formulation	Pharmaceutical gaseous nitric oxide (NO)
Mechanism	Selective pulmonary vasodilation
Delivery System	Nitric Oxide Delivery Systems (NOx systems)
Approved Indications	Neonatal pulmonary hypertension, persistent pulmonary hypertension of the newborn (PPHN), acute respiratory distress syndrome (ARDS)

Regulatory Status: Approved and marketed in the US (FDA) since 1999, with additional approvals in Europe and other regions.

---

Market Size and Segments

Global Market Valuation (2022): $400 million (approximate) with a forecast CAGR of 4-5% through 2030.

Market Segment	Growth Drivers	Revenue Share (2022)
Neonatology	Incidence of PPHN, neonatal ICU protocols	50%
Critical Care	ARDS, ECMO procedures	30%
Other Indications	Pulmonary hypertension treatments	20%

Note: Market figures derived from industry reports (e.g., MarketWatch, 2023), with projections influenced by shifts in critical care practices.

---

Key Market Dynamics

Demand Drivers

• Incidence of Neonatal Pulmonary Hypertension: Globally rising due to prematurity and congenital conditions.
• Critical Care Trends: Increased use in ARDS, especially accelerated by COVID-19, enhances demand.
• Regulatory Approvals and Off-label Use: Expansion into new indications can boost sales.
• Technological Advances: Improved delivery systems increasing safety and efficiency.

Competitive Landscape

Key Players	Market Share (Estimated)	Strengths
Mallinckrodt Pharmaceuticals	Approx. 60%	Established presence, broad portfolio
COVIDIEN/Medtronic	Approx. 20%	Advanced delivery systems
Emerging Generics and Suppliers	20%	Cost competitiveness, regional expansion

Market Challenges

• High Production & Storage Costs: Nitric oxide gas requires specialized manufacturing, storage, and delivery infrastructure.
• Regulatory Hurdles: Strict approvals and safety protocols limit rapid expansion.
• Competition from Alternatives: Other vasodilators or non-invasive therapies (e.g., sildenafil) can limit growth.
• Safety & Usage Risks: Potential toxicities and mishandling consequences constrain usage in some settings.

---

Financial Trajectory: Revenue, Costs, and Profitability

Revenue Projections (2023-2030)

Year	Estimated Global Revenue	Assumptions
2023	$410 million	Steady growth, new indications
2025	$445 million	Expanded use in ARDS, COVID-19 legacy
2030	$550 million	Market penetration, emerging markets

Cost Structure

Cost Component	% of Revenue	Description
Manufacturing & Supply	40-50%	Gas production, delivery systems
R&D	5-8%	Formulation improvements, new indications
Regulatory & Compliance	10-15%	Clinical trials, approvals
Marketing & Distribution	15-20%	Hospital sales, physician outreach

Profitability Outlook

While currently profitable for established manufacturers, margins are sensitive to regulatory costs and competitive pricing. Estimated gross margins are around 50%, with net margins between 10-15%, subject to market expansion efforts.

---

Investment Risks and Opportunities

Risks

Factor	Impact	Mitigation
Regulatory Delays	Reduced market access	Early engagement with authorities
Competitive Pressure	Price erosion	Innovation, expanding indications
Supply Chain Disruptions	Production stoppages	Diversification of suppliers
Technological Shifts	Replaced by alternative therapies	Continuous R&D investment

Opportunities

Factor	Implication	Strategies
New Indications	Growth in ARDS, COVID-related uses	Clinical trials, licensing
Emerging Markets	Untapped patient populations	Local manufacturing, partnerships
Technology Innovation	Improved safety, efficacy	Advanced delivery systems

---

Comparative Analysis With Similar Therapeutics

Aspect	GENOSYL (Nitric Oxide)	Sildenafil (Revatio)	Iloprost (Ventavis)
Type	Gaseous vasodilator	Oral/ph inhaled	Inhaled prostacyclin analogue
Indications	Pulmonary hypertension, neonatal PPHN	Pulmonary arterial hypertension	Pulmonary hypertension, COPD
Market Size (2022)	~$400M	~$1.2B	~$300M
Growth Rate (2022-2030)	4-5%	2-3%	3-4%
Regulatory Status	Approved in multiple regions	Approved globally	Approved in selected markets

This comparison underlines GENOSYL's niche positioning but also indicates a competitive pressure from other classes of vasodilators.

---

Policy and Regulatory Environment

• FDA Regulations: Strict oversight with post-market surveillance.
• EMA & Global Policies: Similar frameworks dictate approval and safety protocols.
• Reimbursement Policies: Reimbursement for ICU medications favors established products like GENOSYL.
• Potential for Off-label Use: Contributes to revenue but raises regulatory scrutiny.

---

Future Outlook and Strategic Considerations

Scenario	Key Factors	Implications
Conservative	Stable demand, limited indication expansion	Slow growth, emphasis on cost-control
Aggressive	New indications, technological innovations	Accelerated revenue growth, market share gain
Disruptive	Introduction of superior therapies	Market contraction, need for innovation

Investors should monitor regulatory developments, clinical trial outcomes, and advancements in pulmonary care therapeutics to assess GENOSYL's long-term viability.

---

Key Takeaways

• Market Fundamentals: The global nitric oxide gas market for medical use is steady with moderate growth, driven by neonatal and critical care needs.
• Revenue Drivers: Incidence of neonatal PPHN and ARDS, especially post-pandemic, sustain demand.
• Competitive Edge: Existing approval network and delivery technology reinforce market position, but margins face pressure from alternative therapies and generics.
• Investment Risks: Regulatory delays, safety concerns, and technological disruption pose threats.
• Growth Opportunities: Expansion into new indications, emerging markets, and innovations in delivery systems present avenues for increased revenue.
• Financial Outlook: Steady revenue growth projected; profitability hinges on operational efficiencies and market expansion.

---

FAQs

Q1: How does GENOSYL’s regulatory pathway influence its market growth?
A1: Regulatory approvals across regions establish market access but involve stringent safety, efficacy, and manufacturing standards, potentially delaying expansion but ensuring product credibility.

Q2: What are the main competitors to GENOSYL, and how do they compare?
A2: Competitors include sildenafil (Revatio) and iloprost (Ventavis). They target similar patient populations with different delivery modes and cost structures, influencing GENOSYL’s market share.

Q3: How might emerging therapies impact GENOSYL in the next decade?
A3: Novel oral or inhaled vasodilators and biologics could reduce reliance on nitric oxide gas, emphasizing the need for GENOSYL to innovate or expand indications.

Q4: What are the key financial metrics to assess GENOSYL’s investment potential?
A4: Revenue growth rate, gross/margin profit, R&D expenditure, market share trends, and regulatory approval pipeline are critical financial indicators.

Q5: Are there geographic markets with higher growth potential for GENOSYL?
A5: Emerging markets in Asia and Latin America, where critical care infrastructure is expanding, offer significant growth opportunities due to increasing ICU admissions and neonatal care.

---

References

1. MarketWatch. (2023). Global Pulmonary Vasodilator Market Size & Trends.
2. FDA. (1999). Approval documents for INOmax.
3. Research and Markets. (2022). Nitric Oxide Therapeutics Market Analysis.
4. National Institutes of Health. (2021). Pulmonary Hypertension in Neonates.
5. Bloomberg Intelligence. (2022). Critical Care Therapeutics Market Outlook.

---

This report aims to empower investors and industry stakeholders with comprehensive insights into GENOSYL, supporting informed decision-making based on current market data and strategic considerations.